Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Peijia Medical Ltd. ( (HK:9996) ) has provided an update.
Peijia Medical Ltd. announced that the National Medical Products Administration of China has accepted the registration application for its TaurusNXT® Non-glutaraldehyde Crosslinked Dry-tissue Transcatheter Aortic Valve Replacement system. This third-generation system features advanced technology aimed at reducing valve calcification and improving procedural safety, which may strengthen Peijia Medical’s position in the innovative medical devices sector.
The most recent analyst rating on (HK:9996) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Ltd. is a company in the medical device industry, focusing on the development of innovative transcatheter valve products. Their primary products include transcatheter aortic valve replacement systems, with a market focus on enhancing the durability and biocompatibility of prosthetic aortic valves.
YTD Price Performance: 39.20%
Average Trading Volume: 1,511,737
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.71B
See more insights into 9996 stock on TipRanks’ Stock Analysis page.